USD 41.14
| ticker | 1 day return % | 1 week return % | 1 month return % | 3 months return % | 6 months return % | 1 year return % | 3 years return % | 5 years return % | 10 years return % | maximum return % |
|---|---|---|---|---|---|---|---|---|---|---|
| RVMD | 0.5 | 2.0 | -7.3 | -12.9 | -11.5 | 49.2 | 84.4 | 42.4 | 42.4 | 42.4 |
| S&P 500 | 0.5 | 2.1 | 1.3 | 5.3 | 12.7 | 25.7 | 38.7 | 85.7 | 197.4 | 34547.3 |
Our interactive price chart includes various drawing tools to help you analyze the product more effectively. Below is a quick guide on how to use these tools: Full Guideline
Feel free to experiment with these tools to enhance your technical analysis. Remember, any drawings you make are temporary and will be lost upon refreshing the page unless saved as an image using the 'Camera' icon.
Get instant AI-powered professional insights on prices:
💡Generate AI Technical Analysis ReportA Multi-Interval Candlestick Chart displays the price movements of an asset over different time intervals. Each candlestick represents the open, high, low, and close prices for a specific interval. The chart can be used to identify trends and patterns in price movements.
| Attribute | Value |
|---|---|
| symbol | RVMD |
| name | Revolution Medicines, Inc. |
| price | 41.14 |
| changes percentage | 0.5376 |
| change | 0.22 |
| day low | 39.96 |
| day high | 41.19 |
| year high | 62.4 |
| year low | 26.95 |
| market cap | 7501879000 |
| price avg 50 | 48.5872 |
| price avg 200 | 43.9668 |
| exchange | NASDAQ |
| volume | 1055569 |
| avg volume | 1667150 |
| open | 40.53 |
| previous close | 40.92 |
| eps | -3.66 |
| pe | -11.24 |
| earnings announcement | 2025-02-24T21:00:00.000+0000 |
| shares outstanding | 182350000 |
| timestamp | 2025-01-23 21:00:01 |
We derive the score of a company's financial statements by evaluating the weighted average sentiment across key within the statements. The cumulative score, normalized to a sum of 1, serves as a metric for assessing the company's performance during the specified period. A higher score indicates stronger performance. However, it's crucial to note that while this score provides valuable insights, it is just one of many factors to consider when making informed investment decisions. A holistic evaluation, considering various aspects of the company's financial health and market conditions, is essential for a well-rounded investment strategy.
| 2023 | 2022 | Y/Y change % | |
|---|---|---|---|
| 0001628171 | |||
| revenue | 11580000 | 35380000 | -67.27 |
| gross profit | 11580000 | 25724000 | -54.98 |
| gross profit ratio | 1 | 0.73 | 37.54 |
| research and development expenses | 423144000 | 253073000 | 67.20 |
| operating expenses | 498765000 | 293659000 | 69.84 |
| interest income | 47482000 | 9154000 | 418.70 |
| interest expense | 303000 | 0 | NaN |
| ebitda | -430582000 | -239469000 | -79.81 |
| ebitdaratio | -37.18 | -7.04 | -428.07 |
| operating income | -487185000 | -258279000 | -88.63 |
| operating income ratio | -42.07 | -7.3 | -476.31 |
| net income | -436367000 | -248705000 | -75.46 |
| net income ratio | -37.68 | -7.03 | -436.06 |
| eps | -3.86 | -3.08 | -25.32 |
Revenue Growth: revenue decreased to 12 million in 2023 from 35 million in 2022 representing a change of -67.27%. This indicates a sales shrinking, which is a negative sign for the company.
Gross Profit: Gross Profit decreased to 12 million in 2023 from 26 million in 2022 representing a change of -54.98%. This indicates a sales profitability decline, which is a negative sign for the company.
Operating Expenses: Operating Expenses increased to 499 million in 2023 from 294 million in 2022 representing a change of 69.84%. The increase in operating expenses can be attributed to various factors such as marketing, administrative costs, and investments in infrastructure. It's important to monitor if these expenses are growing at a sustainable rate compared to revenue.
Earnings per Share (EPS): EPS increased to -3.86 in 2023 from -3.86 in 2022 representing a change of -25.32%. This indicates that the company's earnings are decreasing and it is becoming less profitable on a per-share basis.
Research and Development (R&D) Expenses: R&D Expenses increased to 423 million in 2023 from 253 million in 2022 representing a change of 67.2%. This shows that the company continues to invest in innovation and product development, which is crucial for long-term growth.
EBITDA: EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) increased to -431 million in 2023 from -239 million in 2022 representing a change of -79.81%. The increase in EBITDA indicates improved operational efficiency and profitability.
Operating Income: Operating income increased to -487 million in 2023 from -258 million in 2022 representing a change of -88.63%. The increase in operating income indicates better operational performance and increased profitability.
Net Income: Net income increased to -436 million in 2023 from -249 million in 2022 representing a change of -75.46%. The increase in net income shows improved profitability and indicates that the company is generating more profit for each dollar of revenue.
| 2024Q3 | 2024Q2 | Q/Q change % | |
|---|---|---|---|
| 0001628171 | |||
| revenue | 0 | 0 | NaN |
| gross profit | 0 | -12775000 | 100.00 |
| gross profit ratio | 0 | 0 | NaN |
| research and development expenses | 151752000 | 134932000 | 12.47 |
| operating expenses | 175712000 | 143868000 | 22.13 |
| interest income | 20411000 | 21487000 | -5.01 |
| interest expense | 0 | 0 | NaN |
| ebitda | -175712000 | -154934000 | -13.41 |
| ebitdaratio | 0 | 0 | NaN |
| operating income | -175712000 | -156643000 | -12.17 |
| operating income ratio | 0 | 0 | NaN |
| net income | -156288000 | -133233000 | -17.30 |
| net income ratio | 0 | 0 | NaN |
| eps | -0.94 | -0.81 | -16.05 |
Gross Profit: Gross Profit increased to 0 million in 2024Q3 from -13 million in 2024Q2 representing a change of 100.0%. This indicates a sales profitability growth, which is a positive sign for the company.
Research and Development (R&D) Expenses: R&D Expenses increased to 152 million in 2024Q3 from 135 million in 2024Q2 representing a change of 12.47%. This shows that the company continues to invest in innovation and product development, which is crucial for long-term growth.
EBITDA: EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) increased to -176 million in 2024Q3 from -155 million in 2024Q2 representing a change of -13.41%. The increase in EBITDA indicates improved operational efficiency and profitability.
Operating Income: Operating income increased to -176 million in 2024Q3 from -157 million in 2024Q2 representing a change of -12.17%. The increase in operating income indicates better operational performance and increased profitability.
Net Income: Net income increased to -156 million in 2024Q3 from -133 million in 2024Q2 representing a change of -17.3%. The increase in net income shows improved profitability and indicates that the company is generating more profit for each dollar of revenue.
Operating Expenses: Operating Expenses increased to 176 million in 2024Q3 from 144 million in 2024Q2 representing a change of 22.13%. The increase in operating expenses can be attributed to various factors such as marketing, administrative costs, and investments in infrastructure. It's important to monitor if these expenses are growing at a sustainable rate compared to revenue.
Earnings per Share (EPS): EPS increased to -0.94 in 2024Q3 from -0.94 in 2024Q2 representing a change of -16.05%. This indicates that the company's earnings are decreasing and it is becoming less profitable on a per-share basis.
| 2023 | 2022 | Y/Y change % | |
|---|---|---|---|
| 0001628171 | |||
| total assets | 2061705000 | 811930000 | 153.93 |
| total liabilities | 235511000 | 126742000 | 85.82 |
| total equity | 1826194000 | 685188000 | 166.52 |
| cash and cash equivalents | 696148000 | 161412000 | 331.29 |
| short term investments | 1156807000 | 483531000 | 139.24 |
| long term investments | 0 | 1737000 | -100.00 |
| total current assets | 1879281000 | 660185000 | 184.66 |
| total non current assets | 182424000 | 151745000 | 20.22 |
| total current liabilities | 143851000 | 61984000 | 132.08 |
| total non current liabilities | 91660000 | 64758000 | 41.54 |
| common stock | 16000 | 9000 | 77.78 |
| retained earnings | -1137708000 | -701341000 | -62.22 |
| total debt | 87944000 | 64205000 | 36.97 |
Total Assets: Total Assets increased to 2,062 million in 2023 from 812 million in 2022 representing a change of 153.93%. Suggesting a growth in asset holdings.
Total Equity: Total Equity increased to 1,826 million in 2023 from 685 million in 2022 representing a change of 166.52%. This indicates an increase in shareholders' equity.
Cash And Cash Equivalents: Cash And Cash Equivalents increased to 696 million in 2023 from 161 million in 2022 representing a change of 331.29%. This indicates an increase in available liquid assets.
Short Term Investments: Short Term Investments increased to 1,157 million in 2023 from 484 million in 2022 representing a change of 139.24%. This indicates an increase in short-term investment holdings.
Total Current Assets: Total Current Assets increased to 1,879 million in 2023 from 660 million in 2022 representing a change of 184.66%. This indicates a better liquidity position.
Common Stock: Common Stock increased to 0 in 2023 from 0 in 2022 representing a change of 77.78%. This indicates an increase in ownership interest.
Total Liabilities: Total Liabilities increased to 236 million in 2023 from 127 million in 2022 representing a change of 85.82%. This indicates an increase in overall liabilities.
Total Current Liabilities: Total Current Liabilities increased to 144 million in 2023 from 62 million in 2022 representing a change of 132.08%. This indicates a higher short-term debt burden.
Retained Earnings: Retained Earnings decreased to -1,138 million in 2023 from -701 million in 2022 representing a change of -62.22%. This indicates an accumulated losses.
Total Debt: Total Debt increased to 88 million in 2023 from 64 million in 2022 representing a change of 36.97%. This indicates an increase in overall debt burden.
| 2024Q3 | 2024Q2 | Q/Q change % | |
|---|---|---|---|
| 0001628171 | |||
| total assets | 1762999000 | 1808437000 | -2.51 |
| total liabilities | 196695000 | 189589000 | 3.75 |
| total equity | 1566304000 | 1618848000 | -3.25 |
| cash and cash equivalents | 201262000 | 275713000 | -27.00 |
| short term investments | 1348219000 | 1315002000 | 2.53 |
| long term investments | 0 | 3031000 | -100.00 |
| total current assets | 1579139000 | 1624730000 | -2.81 |
| total non current assets | 183860000 | 183707000 | 0.08 |
| total current liabilities | 110863000 | 105332000 | 5.25 |
| total non current liabilities | 85832000 | 84257000 | 1.87 |
| common stock | 16000 | 16000 | 0.00 |
| retained earnings | -1543232000 | -1386944000 | -11.27 |
| total debt | 86706000 | 8332000 | 940.64 |
Total Assets: Total Assets decreased to 1,763 million in 2024Q3 from 1,808 million in 2024Q2 representing a change of -2.51%. Suggesting a decrease in asset holdings.
Total Liabilities: Total Liabilities increased to 197 million in 2024Q3 from 190 million in 2024Q2 representing a change of 3.75%. This indicates an increase in overall liabilities.
Total Equity: Total Equity decreased to 1,566 million in 2024Q3 from 1,619 million in 2024Q2 representing a change of -3.25%. This indicates a decrease in shareholders' equity.
Cash And Cash Equivalents: Cash And Cash Equivalents decreased to 201 million in 2024Q3 from 276 million in 2024Q2 representing a change of -27.0%. This indicates a decrease in available liquid assets.
Total Current Assets: Total Current Assets decreased to 1,579 million in 2024Q3 from 1,625 million in 2024Q2 representing a change of -2.81%. This indicates a worsen liquidity position.
Total Current Liabilities: Total Current Liabilities increased to 111 million in 2024Q3 from 105 million in 2024Q2 representing a change of 5.25%. This indicates a higher short-term debt burden.
Retained Earnings: Retained Earnings decreased to -1,543 million in 2024Q3 from -1,387 million in 2024Q2 representing a change of -11.27%. This indicates an accumulated losses.
Total Debt: Total Debt increased to 87 million in 2024Q3 from 8 million in 2024Q2 representing a change of 940.64%. This indicates an increase in overall debt burden.
Short Term Investments: Short Term Investments increased to 1,348 million in 2024Q3 from 1,315 million in 2024Q2 representing a change of 2.53%. This indicates an increase in short-term investment holdings.
| 2023 | 2022 | Y/Y change % | |
|---|---|---|---|
| 0001628171 | |||
| net change in cash | 536030000 | 52915000 | 913.00 |
| operating cash flow | -350572000 | -224401000 | -56.23 |
| free cash flow | -358301000 | -235217000 | -52.33 |
| capital expenditure | -7729000 | -10816000 | 28.54 |
| depreciation and amortization | 9309000 | 9656000 | -3.59 |
| deferred income tax | -3910000 | -419000 | -833.17 |
| stock based compensation | 61772000 | 31196000 | 98.01 |
| accounts payables | 32469000 | 7288000 | 345.51 |
| inventory | 0 | 0 | NaN |
| acquisitions net | 0 | 13300000 | -100.00 |
| investments in property plant and equipment | -7729000 | -10816000 | 28.54 |
| net cash used for investing activites | -342598000 | -24116000 | -1320.63 |
| debt repayment | 0 | 0 | NaN |
| common stock issued | 385759000 | 298045000 | 29.43 |
| common stock repurchased | 3317000 | 0 | NaN |
| dividends paid | 0 | 0 | NaN |
| net cash used provided by financing activities | 1229200000 | 301432000 | 307.79 |
| cash at end of period | 699179000 | 163149000 | 328.55 |
| accounts receivables | 3419000 | 1256000 | 172.21 |
| cash at beginning of period | 163149000 | 110234000 | 48.00 |
Net Change in Cash: Net Change in Cash increased to 536 million in 2023 from 53 million in 2022 representing a change of 913.0%. Indicating an increased ability to generate cash from the company's operations or its cash flow position.
Operating Cash Flow: Operating Cash Flow decreased to -351 million in 2023 from -224 million in 2022 representing a change of -56.23%. This indicates that the company generated less cash from its core business operations.
Free Cash Flow: Free Cash Flow decreased to -358 million in 2023 from -235 million in 2022 representing a change of -52.33%. This indicates a decrease in cash generated after accounting for capital expenditures.
Capital Expenditure: Capital Expenditure increased to -8 million in 2023 from -11 million in 2022 representing a change of 28.54%. This indicates an increase in the cash outflow required for acquiring or improving long-term assets.
Stock-Based Compensation: Stock-Based Compensation increased to 62 million in 2023 from 31 million in 2022 representing a change of 98.01%. This indicates increased expenses, which is generally considered a negative sign from a financial perspective.
Accounts Payables: The absolute value of Accounts Payables increased to 32 million in 2023 from 7 million in 2022 representing a change of 345.51%. This indicates that the company has increased its outstanding obligations to its suppliers.
Accounts Receivables: Accounts Receivables increased to 3 in 2023 from 1 million in 2022 representing a change of 172.21%. This suggests that the company is less capable of collecting payments from its customers.
| 2024Q3 | 2024Q2 | Q/Q change % | |
|---|---|---|---|
| 0001628171 | |||
| operating cash flow | -130419000 | -128167000 | -1.76 |
| free cash flow | -133939000 | -130566000 | -2.58 |
| capital expenditure | -3520000 | -2399000 | -46.73 |
| depreciation and amortization | 66000 | 2797000 | -97.64 |
| deferred income tax | 0 | 0 | NaN |
| stock based compensation | 20775000 | 19775000 | 5.06 |
| accounts receivables | 0 | 0 | NaN |
| accounts payables | -2788000 | -4080000 | 31.67 |
| inventory | 0 | 0 | NaN |
| acquisitions net | 0 | 0 | NaN |
| investments in property plant and equipment | -3520000 | -2399000 | -46.73 |
| net cash used for investing activites | -21469000 | 107944000 | -119.89 |
| debt repayment | 0 | 0 | NaN |
| common stock issued | 74293000 | 7504000 | 890.05 |
| common stock repurchased | 0 | 3164000 | -100.00 |
| dividends paid | 0 | 0 | NaN |
| net cash used provided by financing activities | 77294000 | 7504000 | 930.04 |
| net change in cash | -74594000 | -12719000 | -486.48 |
| cash at end of period | 204150000 | 278744000 | -26.76 |
| cash at beginning of period | 278744000 | 291463000 | -4.36 |
Net Change in Cash: Net Change in Cash decreased to -75 million in 2024Q3 from -13 million in 2024Q2 representing a change of -486.48%. Indicating a declined ability to generate cash from the company's operations or its cash flow position.
Operating Cash Flow: Operating Cash Flow decreased to -130 million in 2024Q3 from -128 million in 2024Q2 representing a change of -1.76%. This indicates that the company generated less cash from its core business operations.
Free Cash Flow: Free Cash Flow decreased to -134 million in 2024Q3 from -131 million in 2024Q2 representing a change of -2.58%. This indicates a decrease in cash generated after accounting for capital expenditures.
Stock-Based Compensation: Stock-Based Compensation increased to 21 million in 2024Q3 from 20 million in 2024Q2 representing a change of 5.06%. This indicates increased expenses, which is generally considered a negative sign from a financial perspective.
Capital Expenditure: Capital Expenditure decreased to -4 million in 2024Q3 from -2 million in 2024Q2 representing a change of -46.73%. This indicates a possible improved efficiency or a shift in the company's strategic priorities.
Accounts Payables: The absolute value of Accounts Payables decreased to 3 million in 2024Q3 from 4 million in 2024Q2 representing a change of 31.67%. This indicates that the company has reduced its outstanding obligations to its suppliers.
We save you time by utilizing Generative AI to summarize earnings transcripts. Our summaries provide a clear insight into the company's current performance, future outlook, and overall sentiment expressed during the call. Click on below links to explore more.
Note: The years mentioned below are fiscal years in accounting.
Q3 2024 Earnings call transcript
EPS represents the portion of a company's profit allocated to each outstanding share of common stock. A higher EPS is generally favorable, indicating stronger profitability on a per-share basis.
Positive EPS: A positive EPS signifies that a company is profitable, it is generally viewed positively, supporting stock value and investor confidence.
Negative EPS: Indicates that a company is operating at a loss, which could lead to negative sentiment, potential stock depreciation, and concerns about the company's financial health.
The Next Earning Date represents when the company plans to release its next set of financial results.
An upward trend in EPS suggests consistent growth in earnings, often leading to increased investor confidence. A downward trend may indicate a decline in earnings, potentially decreasing investor confidence and stock value. Fluctuating EPS suggests unpredictable financial performance, warranting cautious investor analysis.
Earnings surprise occurs when a company's actual earnings differ from analysts' expectations. A positive earnings surprise typically reflects better-than-expected performance, potentially leading to stock appreciation. Conversely, a negative earnings surprise can result in stock depreciation. An earnings surprise of zero means the earnings met expectations, which typically has a neutral impact on stock price.
Discover detailed analyst recommendations for stocks, including categories such as Buy, Hold, Sell, Strong Buy, and Strong Sell. These insights are based on thorough analysis of financial and market factors. The consensus is calculated by assigning a numerical score to each recommendation. These scores are then weighted and averaged over a specified period to provide a comprehensive view of the stock's outlook, with the final score determining the overall consensus.
| 2023-12-31 | 2022-12-31 | Y/Y change % | |
|---|---|---|---|
| FY | |||
| calendar year | 2023 | 2022 | NaN |
| revenue per share | 0.1 | 0.44 | -76.68 |
| net income per share | -3.86 | -3.08 | -25.02 |
| operating cash flow per share | -3.1 | -2.78 | -11.32 |
| free cash flow per share | -3.17 | -2.92 | -8.54 |
| cash per share | 16.38 | 8.0 | 104.72 |
| book value per share | 16.14 | 8.5 | 89.92 |
| tangible book value per share | 15.5 | 7.59 | 104.28 |
| shareholders equity per share | 16.14 | 8.5 | 89.92 |
| interest debt per share | 0.78 | 0.8 | -2.06 |
| market cap | 3245138242.92 | 1920523825.5 | 68.97 |
| enterprise value | 2636934242.92 | 1823316825.5 | 44.62 |
| pe ratio | -7.44 | -7.72 | 3.70 |
| price to sales ratio | 280.24 | 54.28 | 416.25 |
| pocfratio | -9.26 | -8.56 | -8.16 |
| pfcf ratio | -9.06 | -8.16 | -10.93 |
| pb ratio | 1.78 | 2.8 | -36.60 |
| ptb ratio | 1.78 | 2.8 | -36.60 |
| ev to sales | 227.71 | 51.54 | 341.86 |
| enterprise value over ebitda | -6.12 | -7.61 | 19.57 |
| ev to operating cash flow | -7.52 | -8.13 | 7.43 |
| ev to free cash flow | -7.36 | -7.75 | 5.06 |
| earnings yield | -0.13 | -0.13 | -3.84 |
| free cash flow yield | -0.11 | -0.12 | 9.85 |
| debt to equity | 0.05 | 0.09 | -48.61 |
| debt to assets | 0.04 | 0.08 | -46.06 |
| net debt to ebitda | 1.41 | 0.41 | 247.97 |
| current ratio | 13.06 | 10.65 | 22.66 |
| interest coverage | -1607.87 | 0 | NaN |
| income quality | 0.8 | 0.9 | -10.96 |
| dividend yield | 0 | 0 | NaN |
| payout ratio | 0 | 0 | NaN |
| sales general and administrative to revenue | 6.53 | 1.15 | 469.27 |
| research and ddevelopement to revenue | 36.54 | 7.15 | 410.85 |
| intangibles to total assets | 0.04 | 0.09 | -61.19 |
| capex to operating cash flow | -0.02 | -0.05 | 54.26 |
| capex to revenue | 0.67 | 0.31 | 118.33 |
| capex to depreciation | 0.83 | 1.12 | -25.88 |
| stock based compensation to revenue | 5.33 | 0.88 | 504.98 |
| graham number | 37.42 | 24.29 | 54.09 |
| roic | -0.25 | -0.34 | 25.67 |
| return on tangible assets | -0.22 | -0.34 | 34.87 |
| graham net net | 14.3 | 6.47 | 121.04 |
| working capital | 1735430000 | 598201000 | 190.11 |
| tangible asset value | 1753847000 | 611773000 | 186.68 |
| net current asset value | 1643770000 | 533443000 | 208.14 |
| invested capital | 1907791000 | 745352000 | 155.96 |
| average receivables | 2963500 | 5301000 | -44.10 |
| average payables | 41547000 | 17681500 | 134.97 |
| average inventory | 0.5 | -6359499.5 | 100.00 |
| days sales outstanding | 39.53 | 48.21 | -18.01 |
| days payables outstanding | 0 | 805.37 | -100.00 |
| days of inventory on hand | 0 | 0.0 | -100.00 |
| receivables turnover | 9.23 | 7.57 | 21.97 |
| payables turnover | 0 | 0.45 | -100.00 |
| inventory turnover | 0 | 9656000 | -100.00 |
| roe | -0.24 | -0.36 | 34.17 |
| capex per share | 0.07 | 0.13 | -49.08 |
ROE: Return on Equity (ROE) increased to -0.24 on 2023-12-31 from -0.36 on 2022-12-31, representing a change of 34.17%. However, ROE is <= 5%, suggesting that the company has not been generating high returns for its shareholders.
Current Ratio: Current Ratio increased to 13.06 on 2023-12-31 from 10.65 on 2022-12-31, representing a change of 22.66%. The current ratio has been increasing, suggesting an increase in the company's short-term liquidity. Since it's above 3, indicating poor management of working capital.
PE Ratio: Price-to-Earnings (P/E) Ratio increased to -7.44 on 2023-12-31 from -7.72 on 2022-12-31, representing a change of 3.70%. Indicating an increase in the relative valuation of the company's stock.
Debt-to-Equity Ratio: Debt-to-Equity Ratio decreased to 0.05 on 2023-12-31 from 0.09 on 2022-12-31, representing a change of -48.61%. The debt-to-equity ratio has been decreasing, indicating that the company has been relying less on debt financing. A ratio of 1 or below is often considered healthy and indicates that the company's total debt is equal to or less than its total equity.
| 2024-09-30 Q3 | 2024-06-30 Q2 | Q/Q change % | |
|---|---|---|---|
| RVMD | |||
| calendar year | 2024 | 2024 | NaN |
| revenue per share | 0 | 0 | NaN |
| net income per share | -0.94 | -0.81 | -16.11 |
| operating cash flow per share | -0.78 | -0.78 | -0.72 |
| free cash flow per share | -0.8 | -0.79 | -1.54 |
| cash per share | 9.29 | 9.63 | -3.59 |
| book value per share | 9.39 | 9.8 | -4.23 |
| tangible book value per share | 8.96 | 9.37 | -4.36 |
| shareholders equity per share | 9.39 | 9.8 | -4.23 |
| interest debt per share | 0.52 | 0.05 | 930.02 |
| market cap | 7566374674.4 | 6409158536.16 | 18.06 |
| enterprise value | 7451818674.4 | 6141777536.16 | 21.33 |
| pe ratio | -12.1 | -12.03 | -0.64 |
| price to sales ratio | 0 | 0 | NaN |
| pocfratio | -58.02 | -50.01 | -16.02 |
| pfcf ratio | -56.49 | -49.09 | -15.08 |
| pb ratio | 4.83 | 3.96 | 22.02 |
| ptb ratio | 4.83 | 3.96 | 22.02 |
| ev to sales | 0 | 0 | NaN |
| enterprise value over ebitda | -42.41 | -39.64 | -6.98 |
| ev to operating cash flow | -57.14 | -47.92 | -19.23 |
| ev to free cash flow | -55.64 | -47.04 | -18.27 |
| earnings yield | -0.02 | -0.02 | 0.64 |
| free cash flow yield | -0.02 | -0.02 | 13.11 |
| debt to equity | 0.06 | 0.01 | 975.55 |
| debt to assets | 0.05 | 0.0 | 967.46 |
| net debt to ebitda | 0.65 | 1.73 | -62.22 |
| current ratio | 14.24 | 15.42 | -7.66 |
| interest coverage | 0 | 0 | NaN |
| income quality | 0.83 | 0.96 | -13.25 |
| dividend yield | 0 | 0 | NaN |
| payout ratio | 0 | 0 | NaN |
| sales general and administrative to revenue | 0 | 0 | NaN |
| research and ddevelopement to revenue | 0 | 0 | NaN |
| intangibles to total assets | 0.04 | 0.04 | 2.19 |
| capex to operating cash flow | -0.03 | -0.02 | -44.19 |
| capex to revenue | 0 | 0 | NaN |
| capex to depreciation | 53.33 | 0.86 | 6118.15 |
| stock based compensation to revenue | 0 | 0 | NaN |
| graham number | 14.07 | 13.34 | 5.45 |
| roic | -0.11 | -0.09 | -16.18 |
| return on tangible assets | -0.09 | -0.08 | -20.44 |
| graham net net | 8.11 | 8.48 | -4.44 |
| working capital | 1468276000 | 1519398000 | -3.36 |
| tangible asset value | 1494759000 | 1547035000 | -3.38 |
| net current asset value | 1382444000 | 1435141000 | -3.67 |
| invested capital | 1638973000 | 1691800000 | -3.12 |
| average receivables | 0 | 0 | NaN |
| average payables | 26887500 | 30848999.5 | -12.84 |
| average inventory | 0 | 0 | NaN |
| days sales outstanding | 0 | 0 | NaN |
| days payables outstanding | 0 | 206.55 | -100.00 |
| days of inventory on hand | 0 | 0 | NaN |
| receivables turnover | 0 | 0 | NaN |
| payables turnover | 0 | 0.44 | -100.00 |
| inventory turnover | 0 | 0 | NaN |
| roe | -0.1 | -0.08 | -21.24 |
| capex per share | 0.02 | 0.01 | 45.23 |
ROE: Return on Equity (ROE) decreased to -0.10 on 2024-09-30 Q3 from -0.08 on 2024-06-30 Q2, representing a change of -21.24%. Suggesting that the company has not been generating high returns for its shareholders.
PE Ratio: Price-to-Earnings (P/E) Ratio decreased to -12.10 on 2024-09-30 Q3 from -12.03 on 2024-06-30 Q2, representing a change of -0.64%. Indicating a decrease in the relative valuation of the company's stock.
Current Ratio: Current Ratio decreased to 14.24 on 2024-09-30 Q3 from 15.42 on 2024-06-30 Q2, representing a change of -7.66%. The current ratio has been declining, suggesting a decrease in the company's short-term liquidity. Since it's above 3, indicating poor management of working capital.
Debt-to-Equity Ratio: Debt-to-Equity Ratio increased to 0.06 on 2024-09-30 Q3 from 0.01 on 2024-06-30 Q2, representing a change of 975.55%. The debt-to-equity ratio has been increasing, indicating that the company has been relying more on debt financing. Higher leverage may increase financial risk. However, a ratio of 1 or below is often considered healthy and indicates that the company's total debt is equal to or less than its total equity.
Negative Sentiment: Discounted Cash Flow value is 4.9 which is lower than current price 41.14, indicates the company may be overvalued.
| Market Capitalization | Enterprise Value | |
|---|---|---|
| Definition | The total market value of a company's outstanding shares | The total market value of a company, including its debt and other liabilities |
| Calculation | Current share price * Total number of outstanding shares | Market capitalization + Total debt - Cash and cash equivalents |
| Focus | Equity component of a company's value | Total economic value of a company |
| Usefulness | Assesses a company's size and growth potential based on investor sentiment | Provides a more comprehensive valuation that considers both equity and debt |
Analyzing dividends is a crucial aspect of investment evaluation, offering valuable insights into a company's financial health and its commitment to shareholder returns. Dividends represent a portion of a company's profits distributed to its shareholders, providing a steady income stream. We help you analyze dividends based on the indicators mentioned below:
• Investors often assess the average dividend amount, observing trends over time to gauge the company's stability and growth potential. A positive trend in average dividends indicates a consistent and potentially lucrative investment. Additionally, evaluating the trend of dividend increases provides insight into the company's financial strength and management's confidence in future earnings.
• Consistency in paying dividends is a reassuring sign, reflecting a company's reliability and commitment to shareholder value. For investors, dividends not only offer income but also contribute to the overall total return on investment.
• Companies with a history of regular and increasing dividends can attract income-focused investors seeking stable returns, making dividends a critical factor in building a well-rounded investment portfolio.
Interested in the overall sentiment for a particular period? Check out our news sentiment analysis tool.
Sentiment: Positive
Publish Date: 2025-01-16 10:35:28
Revolution Medicines (RVMD) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Sentiment: Positive
Publish Date: 2025-01-06 16:05:00
REDWOOD CITY, Calif., Jan. 06, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing novel targeted therapies for patients with RAS-addicted cancers, today announced that Mark A. Goldsmith, M.D., Ph.D., the company's chief executive officer and chairman, will deliver a corporate presentation as part of the 43r d Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025 at 10:30 a.m. PT.
Sentiment: Positive
Publish Date: 2024-12-15 08:20:56
The year is winding down, and the stock markets are near all-time highs. Opinions on what the new year will bring vary wildly.
Sentiment: Negative
Publish Date: 2024-12-05 16:05:00
Underwriters' full exercise of option brings gross proceeds to $862.5 million Underwriters' full exercise of option brings gross proceeds to $862.5 million
Sentiment: Positive
Publish Date: 2024-12-04 09:09:18
Revolution Medicines' stock has surged over 30% since April, driven by promising clinical data for its lead asset, RMC-6236, targeting RAS-mutated cancers. RMC-6236 shows best-in-class efficacy in PDAC, with potential expansion into NSCLC and CRC, positioning it as a potential new standard of care. Despite a recent stock dip due to a $600m public offering, Revolution's robust cash position and promising pipeline offer significant long-term potential.
Sentiment: Positive
Publish Date: 2024-12-03 22:38:00
REDWOOD CITY, Calif., Dec. 03, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced the pricing of 14,130,436 shares of its common stock at a public offering price of $46.00 per share, before underwriting discounts and commissions, and, in lieu of shares of common stock, to certain investors, pre-funded warrants to purchase 2,173,917 shares of common stock at a public offering price of $45.9999, which represents the per share public offering price for the common stock less the $0.0001 per share exercise price for each pre-funded warrant. All of the shares and pre-funded warrants in the offering are to be sold by Revolution Medicines. In addition, Revolution Medicines has granted the underwriters a 30-day option to purchase up to an additional 2,445,652 shares of common stock at the public offering price, less underwriting discounts and commissions. The gross proceeds from the offering are expected to be approximately $750.0 million before deducting underwriting discounts and commissions and other offering expenses, excluding any exercise of the underwriters' option to purchase additional shares and excluding the exercise of any pre-funded warrants. The offering is expected to close on December 5, 2024, subject to customary closing conditions.
Sentiment: Positive
Publish Date: 2024-12-02 16:31:00
REDWOOD CITY, Calif., Dec. 02, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced that it has commenced an underwritten public offering to sell up to $600.0 million of shares of its common stock. All of the shares of common stock are being offered by Revolution Medicines. In addition, Revolution Medicines intends to grant the underwriters a 30-day option to purchase up to an additional $90.0 million of shares of common stock. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
Sentiment: Positive
Publish Date: 2024-12-02 07:30:00
Compelling Phase 1/1b update on RMC-6236 monotherapy in second-line metastatic pancreatic ductal adenocarcinoma supports ongoing Phase 3 RASolute 302 clinical trial
Sentiment: Negative
Publish Date: 2024-11-27 16:05:00
REDWOOD CITY, Calif., Nov. 27, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced that it will host an investor webcast to provide clinical updates from its RAS(ON) inhibitor portfolio.
Sentiment: Neutral
Publish Date: 2024-11-06 19:52:10
Revolution Medicines, Inc. (RVMD) Q3 2024 Earnings Call Transcript
Sentiment: Positive
Publish Date: 2024-11-06 16:02:00
Phase 3 pivotal trial underway evaluating RMC-6236 in patients with metastatic pancreatic ductal adenocarcinoma (PDAC), supported by compelling clinical profile
Sentiment: Positive
Publish Date: 2024-11-05 09:00:00
REDWOOD CITY, Calif., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today announced that Mark A. Goldsmith, M.D., Ph.D., the company's chief executive officer and chairman, will be a featured speaker at Guggenheim's Inaugural Healthcare Innovation Conference and the UBS Global Healthcare Conference.
Sentiment: Positive
Publish Date: 2024-10-30 16:05:00
REDWOOD CITY, Calif., Oct. 30, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced that it will report financial results for the third quarter 2024 on Wednesday, November 6, 2024, after market close. At 4:30 p.m. Eastern Time that day (1:30 p.m. Pacific Time), members of Revolution Medicines' senior management team will host a webcast to discuss the financial results for the quarter and provide an update on corporate progress.
* The sentiment analysis presented is generated through an algorithm and may be subject to inaccuracies. Users are advised to corroborate key information and employ further analytical methods prior to making critical decisions.
Get instant AI-powered professional insights:
💡Generate AI Technical Analysis ReportUnderstand the chart below:
Interpret Technical Indicators
| Indicator | Bullish | Bearish |
|---|---|---|
| Price and EMA ⓘ | Price crosses above EMA | Price crosses below EMA |
| Short-Term vs Long-Term EMA ⓘ | Short EMA crosses above Long EMA | Short EMA crosses below Long EMA |
| Volume ⓘ | Increasing volume during price uptrend | Increasing volume during price downtrend |
| MACD ⓘ | MACD crosses above Signal Line | MACD crosses below Signal Line |
| RSI ⓘ | RSI is below 30 (oversold) and starts to rise above 30 | RSI is above 70 (overbought) and starts to decline below 70 |
| Candlestick Patterns ⓘ | Bullish candlestick patterns | Bearish candlestick patterns |
Copyright © 2024 Sirius Investors
All rights reserved
